Clinical Trials Logo
  1. Home
  2. Breast Cancer
  3. NCT00246961
  4. Details
NCT00246961 Clinical Trial

Arimidex Observational: Reason for and Effect of Change From Tamoxifen

Breast Cancer Clinical Trial

— ARREST  

Official title:
Arimidex: Reason for and Effect of Change From Tamoxifen

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00246961
Other study ID # D5392NL0002
Secondary ID ARREST
Status Completed
Phase Phase 4
First received October 31, 2005
Last updated October 11, 2007
Start date July 2004

Study information
Verified date June 2007
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority Netherlands: Dutch Health Care Inspectorate
Study type Observational

Clinical Trial Summary

The purpose of this study is to analyse the effect on quality of life after 3 months of treatment after changing adjuvant therapy from tamoxifen to Arimidex.

Recruitment information / eligibility
Status Completed
Enrollment 200
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Postmenopausal

- Hormone sensitive breast cancer

- Patient uses tamoxifen or has stopped taking tamoxifen less than 7 days ago

Exclusion Criteria:

- Visceral metastases

- Patients with signs of progression at the moment of changing therapy

- Patients who have used other endocrine treatments for breast cancer besides tamoxifen

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

Locations
Country Name City State
Netherlands Research Site 'S-Gravenhage
Netherlands Research Site 's-Hertogenbosch
Netherlands Research Site Alkmaar
Netherlands Research Site Antwerpen
Netherlands Research Site Apeldoorn
Netherlands Research Site Bergen op Zoom
Netherlands Research Site Boxmeer
Netherlands Research Site Breda
Netherlands Research Site Doetinchem
Netherlands Research SIte Dordrecht
Netherlands Research Site Ede
Netherlands Research Site Eindhoven
Netherlands Research Site Enschede
Netherlands Research Site Geldrop
Netherlands Research Site Groningen
Netherlands Research Site Harderwijk
Netherlands Research Site Helmond
Netherlands Research Site Hoogeveen
Netherlands Research Site Hoorn
Netherlands Research Site Leiden
Netherlands Research Site Oosterhout
Netherlands Research Site Purmerend
Netherlands Research Site Roermond
Netherlands Research Site Roosendaal
Netherlands Research Site Rotterdam
Netherlands Research Site Schiedam
Netherlands Research Site Terneuzen
Netherlands Research Site Tiel
Netherlands Research Site Venray
Netherlands Research Site Vlissingen
Netherlands Research Site Winterswijk
Netherlands Research Site Zoetermeer
Netherlands Research Site Zutphen

Sponsors (1)
Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

Netherlands, 

See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A